Organ at Risk Dose Constraints in SABR: A Systematic Review of Active Clinical Trials

SABR波动模型 医学 临床试验 四分位间距 医学物理学 核医学 放射科 外科 内科学 随机波动 波动性(金融) 金融经济学 经济
作者
Serenna G. Gerhard,David A. Palma,Andrew Arifin,Alexander V. Louie,Li G,Faiez Al-Shafa,Patrick Cheung,George Rodrigues,Carol W. Bassim,Mark T. Corkum
出处
期刊:Practical radiation oncology [Elsevier BV]
卷期号:11 (4): e355-e365 被引量:60
标识
DOI:10.1016/j.prro.2021.03.005
摘要

Organ at risk (OAR) dose constraints are a critical aspect of SABR treatment planning. There is limited evidence supporting preferred dose constraints for many OARs. We sought to evaluate OAR dose constraints used in ongoing clinical trials of SABR for oligometastatic disease.Clinicaltrials.gov was searched from inception to February 2020 to capture actively accruing clinical trials using SABR in oligometastatic disease. Dose constraints were obtained by contacting principal investigators and abstracted by 2 authors. Variability of constraints was assessed by comparing the width of the interquartile range and difference between the maximum and minimum dose to a volume.Fifty-three of 85 eligible clinical trials contributed OAR constraints used in analysis. Dose constraints for 1 to 8 fractions of SABR were collected for 33 OARs. Variability was found in the absolute allowable OAR doses, use of planning OAR volumes, and whether constraints were optional versus mandatory. For many OARs, modal dose constraints often matched a pre-existing publication, but no single pre-existing publication matched the modes of all OAR dose constraints. Organs displaying the most variability were the rectum, penile bulb, and chest wall and ribs. The esophagus, stomach, duodenum, and small bowel also indicated high variability for at least 1 constraint. OARs previously evaluated by HyTEC appeared to have less variability among study protocols.We found substantial variability in OAR dose constraints used in current clinical trials evaluating SABR in oligometastatic disease. We are unable to comment on toxicity rates or acceptability of dose constraints used. Future research and recommendations for standardized OAR dose constraints, as well as consistency in implementing planning OAR volume margins, should be priorities for the field of radiation oncology.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
在九月完成签到 ,获得积分10
1秒前
酷酷怜雪完成签到 ,获得积分10
1秒前
1秒前
2秒前
吕奎完成签到,获得积分10
2秒前
爱撒娇的朋友完成签到,获得积分10
2秒前
yongziwu完成签到,获得积分0
2秒前
Amy完成签到,获得积分0
3秒前
3秒前
啦啦啦完成签到 ,获得积分10
3秒前
儒雅山兰完成签到,获得积分10
4秒前
daikai完成签到,获得积分10
4秒前
Sevi完成签到,获得积分10
4秒前
4秒前
Huangzhisong发布了新的文献求助10
5秒前
我爱坏女人完成签到,获得积分20
5秒前
潇洒的辣条完成签到,获得积分10
5秒前
Cc发布了新的文献求助10
5秒前
弹指一挥间完成签到,获得积分10
5秒前
甜屁儿完成签到 ,获得积分10
5秒前
5秒前
暖阳完成签到 ,获得积分10
5秒前
zdl完成签到,获得积分10
6秒前
6秒前
超级大肥宅完成签到,获得积分10
6秒前
一土它小木登子完成签到,获得积分10
7秒前
好嘞完成签到 ,获得积分10
7秒前
yy发布了新的文献求助10
7秒前
7秒前
SHUNLI0205发布了新的文献求助10
8秒前
8秒前
李健的粉丝团团长的应助被dde采纳,获得10
9秒前
科研通AI6.4的应助被dde采纳,获得10
9秒前
科研通AI6.4的应助被dde采纳,获得10
9秒前
彭于晏的应助被dde采纳,获得10
9秒前
why完成签到,获得积分10
9秒前
Lucas的应助被dde采纳,获得10
9秒前
科研通AI6.4的应助被dde采纳,获得10
9秒前
西梅完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8152197
求助须知:如何正确求助?哪些是违规求助? 9548933
关于积分的说明 21688809
捐赠科研通 7740419
什么是DOI,文献DOI怎么找? 3425136
关于科研通互助平台的介绍 2550342
邀请新用户注册赠送积分活动 2468584